HSBC Continental Europe
HSBC Continental Europe: Post Stabilisation Notice
HSBC Continental Europe: Post Stabilisation Notice
PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) --
Assicurazioni Generali S.p.A.
Post Stabilisation Notice
HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice that no stabilisation was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
Issuer: | Assicurazioni Generali S.p.A. |
Guarantor (if any): | na |
Aggregate nominal amount: | EUR 500,000,000 |
Description: | 4.083% due 16th July 2035 |
Offer price: | 100 |
Stabilising Manager: | HSBC Continental Europe |
This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Standard Lithium9.5.2025 14:30:02 CEST | Press release
Standard Lithium Reports Fiscal First Quarter 2025 Results
Norsk Hydro9.5.2025 14:15:00 CEST | Press release
Norsk Hydro: Minutes from the Annual General Meeting 2025
Global Center on Adaptation9.5.2025 14:03:25 CEST | Press release
GCA Welcomes Denmark’s Ole Thonke to its Advisory Board
Nykredit Realkredit A/S9.5.2025 13:58:00 CEST | Pressemeddelelse
Ledende medarbejdere og disses nærtstående transaktioner - Nykredit Realkredit A/S
Akero Therapeutics Inc.9.5.2025 13:41:09 CEST | Press release
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom